Status:
COMPLETED
Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Studying samples of blood in the laboratory from patients receiving pemetrexed disodium may help doctors learn more about the effects of pemetrexed disodium on cells. It may also help docto...
Detailed Description
OBJECTIVES: Primary * Assess the intracellular level of pemetrexed disodium (PD) polyglutamates as a measure of activity of PD transport and activation enzymes in patients with stage III or IV non-s...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Enrolled in clinical trial MCCRC-RC0524
- Willing to provide blood samples
- PATIENT CHARACTERISTICS:
- No investigator site personnel directly affiliated with the study, or immediate family of investigator site personnel directly affiliated with the study
- Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted
- Not employed by Eli Lilly (i.e., employee, temporary contract worker, or designee responsible for conducting the study)
- Immediate family of Eli Lilly employees allowed, but may not participate at an Eli Lilly facility
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
November 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2007
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00898820
Start Date
November 1 2006
End Date
December 1 2007
Last Update
April 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905